AnaptysBio, Inc

(NASDAQ:ANAB)

Latest On AnaptysBio, Inc (ANAB):

Date/Time Type Description Signal Details
2023-05-22 18:46 ESTNewsAnaptysBio upgraded to neutral at JP Morgan on clinical executionN/A
2023-05-21 00:00 ESTNewsStocks To Watch: Debt Ceiling Drama, Nvidia Earnings And Healthcare ConferencesN/A
2023-05-18 17:01 ESTNewsAnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agentsN/A
2023-05-12 06:14 ESTNewsAnaptysBio GAAP EPS of -$1.58 misses by $0.53, revenue of $1.4M misses by $1.48MN/A
2023-04-25 14:45 ESTNewsGSK's Jemperli gets review in EU for expanded use in uterus cancerN/A
2023-03-31 01:05 ESTNewsAnaptysBio: Upside Could Be Lying Ahead Very NicelyN/A
2023-03-01 22:46 ESTNewsAnaptysBio GAAP EPS of -$0.93, revenue of $6.8MN/A
2023-01-13 19:42 ESTNewsAnaptysBio rises 10% on stock repurchase of up to $50MN/A
2022-11-09 02:12 ESTNewsAnaptysBio GAAP EPS of -$1.18 misses by $0.56, revenue of $1.29M misses by $12.14MN/A
2022-11-01 22:23 ESTNewsAnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonistsN/A
2022-10-05 18:17 ESTNewsAnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trialN/A
2022-09-14 00:51 ESTNewsAnaptysBio cut to Hold at Truist citing high bar for hair loss treatmentN/A
2022-09-12 13:42 ESTNewsAnaptysBio sells royalties from GSK-partnered Zejula for $45MN/A
2022-09-01 01:51 ESTNewsAnaptysBio skin condition candidate fails mid-stage trial; shares down 16%N/A
2022-08-08 18:55 ESTNewsAnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4MN/A
2022-05-04 22:42 ESTNewsAnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08MN/A
2022-03-22 16:43 ESTNewsAnaptysBio names interim CEO as Hamza Suria steps downN/A
2022-03-22 16:42 ESTNewsAnaptysBio cut to neutral at Guggenheim on future of pipelineN/A
2022-03-14 23:38 ESTNewsAnaptysBio acne treatment imsidolimab fails in mid-stage trial; shares down 12%N/A
2021-11-05 01:02 ESTNewsAnaptysBio EPS beats by $0.64, beats on revenueN/A
2021-10-26 12:05 ESTNewsAnaptysBio climbs 14%, will monetize portion of JEMPERLI royalties for $250M with SagardN/A
2021-10-04 23:16 ESTNewsAnaptysBio reports updated data from imsidolimab mid-stage study in pustular psoriasisN/A
2021-08-18 04:46 ESTNewsAnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approvalN/A
2021-08-18 04:46 ESTNewsANAB, TLRY, PFMT and BMRN among after hours moversN/A
2021-08-09 22:59 ESTNewsAnaptysBio EPS beats by $0.12, beats on revenueN/A
2021-07-20 18:44 ESTNewsAnaptysBio gains after report the company received a takeover offerN/A
2021-05-05 11:31 ESTNewsAnaptysBio EPS beats by $0.03, beats on revenueN/A
2021-04-24 05:15 ESTNewsAnaptysBio trades higher after FDA approval for Jemperli triggers $20M milestone paymentN/A
2021-04-24 05:14 ESTNewsGlaxoSmithKline wins EU approval for Jemperli in endometrial cancerN/A
2021-04-23 07:49 ESTNewsAnaptysBio is trading higher after FDA approval for Jemperli in endometrial cancer (updated)N/A
2021-03-17 12:05 ESTAnalyst RatingThe Analyst Target Price has increased from $26.75 to $28.5.Buy
2021-03-16 19:18 ESTNewsAnaptysBio is set for a catalyst-rich phase after the recent selloff: TruistN/A
2021-03-10 15:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $30.75 to $26.75.Neutral
2021-03-09 03:06 ESTAnalyst RatingThe Analyst Target Price has decreased from $33.25 to $30.75.Neutral
2021-03-08 17:28 ESTNewsAnaptysBio fails in mid-stage study for Imsidolimab in skin diseaseN/A
2021-03-08 17:27 ESTNewsAnaptysBio gets double downgrade at JPM after Imsidolimab trial failureN/A
2021-03-03 02:39 ESTNewsAnaptysBio: Upcoming Catalyst Seems Like Quite The GambleN/A
2021-03-01 15:05 ESTAnalyst RatingThe Analyst Target Price has increased from $29.8 to $33.25.Buy
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$2.43 is estimated for the 2022 year.Sell
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$0.69 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-26 15:05 ESTFinancialsCompany financials have been released.Neutral
2021-02-25 19:20 ESTNewsAnaptysBio EPS beats by $0.15, beats on revenueN/A
2021-02-12 11:05 ESTAnalyst RatingThe Analyst Target Price has increased from $28 to $29.8.Neutral
2021-02-11 20:59 ESTNewsAnaptysBio rises after double-upgrade from JPM; positive risk/reward profile citedN/A
2021-02-11 20:58 ESTNewsAnaptysBio: Troubled History Of Drug DevelopmentN/A
2020-12-13 03:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-01 10:36 ESTNewsAnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% UpsideN/A
2020-11-18 06:57 ESTNewsAnaptysBio (ANAB) Investor Presentation - SlideshowN/A
2020-11-15 11:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 11:07 ESTAnalyst RatingThe Analyst Target Price has increased from $27.5 to $28.Neutral

About AnaptysBio, Inc (ANAB):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

ANAB Quotes by TradingView

See Advanced Chart

General

  • Name AnaptysBio, Inc
  • Symbol ANAB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 94
  • Fiscal Year EndDecember
  • IPO Date2017-01-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anaptysbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 8.07
  • Price/Book (Most Recent Quarter) 1.53
  • Enterprise Value Revenue 2.85
  • Enterprise Value EBITDA 0.11
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.01
  • Next Year EPS Estimate -$3.09
  • Next Quarter EPS Estimate -$0.61
  • Profit Margin -27%
  • Operating Margin -32%
  • Return on Assets -4%
  • Return on Equity -5%
  • Revenue 75 million
  • Earnings Per Share -$3.01
  • Revenue Per Share $2.75
  • Gross Profit -5025000
  • Quarterly Earnings Growth 1900%
View More

Highlights

  • Market Capitalization 587.28 million
  • EBITDA -87543000
  • PE Ratio -6.14
  • Analyst Target Price $28.5
  • Book Value Per Share $14.50
View More

Share Statistics

  • Shares Outstanding 27.37 million
  • Shares Float 15.89 million
  • % Held by Insiders 77%
  • % Held by Institutions 106.22%
  • Shares Short 3.81 million
  • Shares Short Prior Month 3.74 million
  • Short Ratio 8.99
  • Short % of Float 21%
  • Short % of Shares Outstanding 14%
View More

Technicals

  • Beta 0.13
  • 52 Week High $35.86
  • 52 Week Low $12.46
  • 50 Day Moving Average 26.72
  • 200 Day Moving Average 23.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AnaptysBio, Inc (ANAB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AnaptysBio, Inc (ANAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$60 million$1.20$0.6098.87%
2020-09-302020-11-04$N/A-$0.87-$0.69-26.45%
2020-06-302020-08-10$N/A-$0.79-$0.65-21.18%
2020-03-312020-05-06$N/A-$0.30-$0.8062.5%
2019-12-312020-03-02$3 million-$0.75-$1.2841.36%
2019-09-302019-11-08$N/A-$1.15-$1.14-0.46%
2019-06-302019-08-08$5 million-$0.89-$0.956.66%
2019-03-312019-05-07$N/A-$0.82-$0.78-4.75%
2018-12-312019-02-28$N/A-$0.64-$0.8625.93%
2018-09-302018-11-08$5 million-$0.66-$0.706.16%
2018-06-302018-08-07$N/A-$0.57-$0.6714.41%
2018-03-312018-05-08$N/A-$0.63-$0.46-36.22%
2017-12-312018-03-05$3 million-$0.30-$0.4228.37%
2017-09-302017-11-07$-7000000-$0.45-$0.474.56%
2017-06-302017-08-10$7 million-$0.13-$0.4269.34%
2017-03-312017-05-11$N/A-$0.75-$0.18-310.96%
2016-12-312017-03-08$2.75 million-$0.19-$0.10-86.34%

AnaptysBio, Inc (ANAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 21.57 million N/A N/A N/A 21.43 million
Income Before Tax 33.65 million N/A N/A N/A -20.29 million
Selling General Administrative 5.09 million N/A N/A N/A 3.83 million
Gross Profit 60 million N/A N/A N/A 3 million
Ebit 36.89 million N/A N/A N/A -22.26 million
Operating Income 33.35 million N/A N/A N/A -22.26 million
Income Tax Expense N/A N/A N/A N/A -22000
Total Revenue 60 million N/A N/A N/A 3 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 1.97 million
Net Income From Continuing Operations 33.65 million N/A N/A N/A -20.26 million
Net Income Applicable to Common Shares 33.65 million -23.77 million -21.55 million -8.26 million -20.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 4.06 million -3.3 million -5.19 million N/A N/A
Total Cash Flow from Investing Activities 4.73 million 75.39 million 10.75 million N/A N/A
Net Borrowings N/A N/A -1.38 million N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities -424000 -2.71 million 233000 N/A N/A
Change in Cash N/A N/A N/A N/A N/A
Total Cash from Operating Activities -17.01 million -19.61 million -15.11 million N/A N/A
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.98 million 2.81 million 2.97 million N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 19.82 million N/A N/A N/A 30.19 million
Total Stockholder Equity 396.73 million N/A N/A N/A 405.01 million
Other Current Liabilities 342000 851000 N/A N/A 871000
Total Assets 416.55 million N/A N/A N/A 435.2 million
Common Stock 27000 27000 27000 27000 27000
Other Current Assets 2.91 million N/A N/A N/A N/A
Retained Earnings -263.96 million -297.6 million -273.84 million -252.29 million -244.03 million
Other Liabilities N/A 33000 180000 N/A 654000
Other Assets N/A 1.17 million 1.41 million 140000 1.54 million
Cash 250.46 million N/A N/A N/A 171.02 million
Total Current Liabilities 19.82 million 24.47 million N/A N/A 29.54 million
Other Stockholder Equity -4000 259000 753000 1.15 million 338000
Property, Plant & Equipment 1.78 million 1.59 million 1.5 million 2.82 million 1.62 million
Total Current Assets 396.56 million 345.81 million N/A N/A 377.73 million
Long Term Investments 17.55 million N/A N/A N/A 54.31 million
Net Tangible Assets 396.73 million 360.24 million 381.44 million 400.56 million 405.01 million
Short Term Investments 143.2 million N/A N/A N/A 203.21 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 19.48 million 5.48 million N/A N/A 16.24 million

AnaptysBio, Inc (ANAB) Chart:

AnaptysBio, Inc (ANAB) News:

Below you will find a list of latest news for AnaptysBio, Inc (ANAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AnaptysBio, Inc (ANAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-2017.50CALL0 0173.61TRUE00
2024-12-20200CALL0 0163.41TRUE00
2024-12-2022.50CALL0 0173.34TRUE00
2024-12-20250CALL0 0156.31TRUE00
2024-12-20300CALL0 0163.99TRUE00
2024-12-20358.8CALL0 5157.87FALSE00
2024-12-204011.2CALL0 11150.94FALSE00
2024-12-20458.3CALL0 16159.02FALSE00
2024-12-20506.7CALL0 37158.8FALSE00
2024-12-20550CALL0 0162.71FALSE00
2024-12-2017.51.57PUT43 1500156.33FALSE1.570
2024-12-20200PUT0 0175.92FALSE00
2024-12-2022.52.35PUT0 100166.37FALSE00
2024-12-20251.9PUT0 50164.71FALSE00
2024-12-20306.8PUT0 36165.92FALSE00
2024-12-203510.4PUT98 3697165.27TRUE10.40
2024-12-204013.8PUT0 15158.53TRUE00
2024-12-204515.3PUT0 47157.8TRUE00
2024-12-20500PUT0 0161.94TRUE00
2024-12-205522.4PUT0 1152.91TRUE00
2025-01-1717.50CALL0 0161.42TRUE00
2025-01-17200CALL0 0166.34TRUE00
2025-01-1722.50CALL0 0155.71TRUE00
2025-01-172513.6CALL0 5173.07TRUE00
2025-01-17309.8CALL0 195160.42TRUE00
2025-01-173510.6CALL0 3159.82FALSE00
2025-01-17409CALL93 3523155.91FALSE90
2025-01-17457.3CALL0 1153.03FALSE00
2025-01-17507.1CALL93 3502148.86FALSE0.30.04
2025-01-17558.85CALL0 2155.74FALSE00
2025-01-1717.52.27PUT0 2054182.69FALSE00
2025-01-17202.7PUT0 3172.16FALSE00
2025-01-1722.53.6PUT0 102163.57FALSE00
2025-01-17256PUT0 2144154.02FALSE00
2025-01-17309.1PUT0 188161.82FALSE00
2025-01-17359.6PUT0 35152.42TRUE00
2025-01-174011.9PUT0 2148.93TRUE00
2025-01-17450PUT0 0161.55TRUE00
2025-01-17500PUT0 0147.25TRUE00
2025-01-17550PUT0 0161.33TRUE00
2025-02-2112.50CALL0 0157.78TRUE00
2025-02-211523.17CALL0 1152.41TRUE00
2025-02-2117.50CALL0 0157.34TRUE00
2025-02-21200CALL0 0147.65TRUE00
2025-02-2122.50CALL0 0157.04TRUE00
2025-02-21250CALL0 0146.3TRUE00
2025-02-21300CALL0 0147.81TRUE00
2025-02-213510.9CALL0 15148.48FALSE00
2025-02-214010CALL0 50143.91FALSE00
2025-02-21458.28CALL0 2138.83FALSE00
2025-02-21500CALL0 0138.06FALSE00
2025-02-215510.3CALL0 4142.93FALSE00
2025-02-2112.50PUT0 00FALSE00
2025-02-21150PUT0 00FALSE00
2025-02-2117.52.4PUT0 21160.04FALSE00
2025-02-21200PUT0 0146.73FALSE00
2025-02-2122.50PUT0 0152.38FALSE00
2025-02-21250PUT0 0147.65FALSE00
2025-02-21308.54PUT0 5138.07FALSE00
2025-02-213511.65PUT0 2142.38TRUE00
2025-02-214013.3PUT0 1141.98TRUE00
2025-02-21450PUT0 0142.93TRUE00
2025-02-21500PUT0 0145.64TRUE00
2025-02-21550PUT0 0141.89TRUE00
2025-03-2117.50CALL0 0144.18TRUE00
2025-03-21200CALL0 0151.22TRUE00
2025-03-2122.50CALL0 0154.63TRUE00
2025-03-21250CALL0 0139.18TRUE00
2025-03-21300CALL0 0147.06TRUE00
2025-03-21350CALL0 0146.02FALSE00
2025-03-21400CALL0 0144.02FALSE00
2025-03-21450CALL0 0141.05FALSE00
2025-03-215012.75CALL0 1137.48FALSE00
2025-03-21550CALL0 0137.19FALSE00
2025-03-2117.50PUT0 0157.1FALSE00
2025-03-21200PUT0 0144.08FALSE00
2025-03-2122.50PUT0 0154.02FALSE00
2025-03-21256.82PUT3 0145.68FALSE6.820
2025-03-21300PUT0 0142.43FALSE00
2025-03-21350PUT0 0142.19TRUE00
2025-03-21400PUT0 0144.66TRUE00
2025-03-21450PUT0 0139.76TRUE00
2025-03-21500PUT0 0141.17TRUE00
2025-03-21550PUT0 0148.4TRUE00
2025-04-1717.50CALL0 0143.78TRUE00
2025-04-17200CALL0 0140.23TRUE00
2025-04-1722.50CALL0 0149.67TRUE00
2025-04-17250CALL0 0144.6TRUE00
2025-04-17300CALL0 0145.09TRUE00
2025-04-173516.55CALL0 0145.66FALSE00
2025-04-17409.05CALL0 0143.17FALSE00
2025-04-174511.41CALL0 217141.55FALSE00
2025-04-17509.44CALL0 1137.97FALSE00
2025-04-17550CALL0 0143.51FALSE00
2025-04-1717.50PUT0 0159.64FALSE00
2025-04-17200PUT0 0154.09FALSE00
2025-04-1722.55.05PUT0 1153.5FALSE00
2025-04-17250PUT0 0146.65FALSE00
2025-04-17300PUT0 0148.04FALSE00
2025-04-17350PUT0 0141.99TRUE00
2025-04-17400PUT0 0144.87TRUE00
2025-04-17450PUT0 0145.54TRUE00
2025-04-17500PUT0 0146.59TRUE00
2025-04-17550PUT0 0145.83TRUE00
2025-05-16200CALL0 0150.84TRUE00
2025-05-1622.521.3CALL0 1145.16TRUE00
2025-05-16250CALL0 0143.28TRUE00
2025-05-16300CALL0 0140.94TRUE00
2025-05-16350CALL0 0139.94FALSE00
2025-05-16400CALL0 0136.86FALSE00
2025-05-16450CALL0 0138.59FALSE00
2025-05-16500CALL0 0134.13FALSE00
2025-05-16550CALL0 0134.66FALSE00
2025-05-16200PUT0 0145.22FALSE00
2025-05-1622.50PUT0 0143.88FALSE00
2025-05-16250PUT0 0142.18FALSE00
2025-05-16300PUT0 0137.72FALSE00
2025-05-16350PUT0 0140.2TRUE00
2025-05-16400PUT0 0139.08TRUE00
2025-05-16450PUT0 0134.37TRUE00
2025-05-16500PUT0 0142.07TRUE00
2025-05-16550PUT0 0141.36TRUE00

Latest ANAB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST8$21.35
Jun 13, 2022 7:59 PM EST1$21.35
Jun 13, 2022 7:59 PM EST200$21.35
Jun 13, 2022 7:59 PM EST54$21.35
Jun 13, 2022 7:59 PM EST13$21.35

AnaptysBio, Inc (ANAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2018-09-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018028147/0000000000-18-028147-index.htm
2018-10-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018032332/0000000000-18-032332-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000009375120000338/0000093751-20-000338-index.htm
2019-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000021545719003201/0000215457-19-003201-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619000857/0000315066-19-000857-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619001800/0000315066-19-001800-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000083423720004777/0000834237-20-004777-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266419000927/0000902664-19-000927-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266420000965/0000902664-20-000965-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092189520000234/0000921895-20-000234-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092963819000269/0000929638-19-000269-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093247119004736/0000932471-19-004736-index.htm
2019-11-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583619000611/0000935836-19-000611-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583620000141/0000935836-20-000141-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000436/0001012975-18-000436-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000437/0001012975-18-000437-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000438/0001012975-18-000438-index.htm
2018-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000107261318000346/0001072613-18-000346-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000110465920018330/0001104659-20-018330-index.htm
2018-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518089132/0001193125-18-089132-index.htm
2018-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518095907/0001193125-18-095907-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518280420/0001193125-18-280420-index.htm
2018-09-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518281156/0001193125-18-281156-index.htm
2018-09-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518283918/0001193125-18-283918-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518283933/0001193125-18-283933-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000119312519041203/0001193125-19-041203-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312520225721/0001193125-20-225721-index.htm
2018-03-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017376/0001209191-18-017376-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017377/0001209191-18-017377-index.htm
2018-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045891/0001209191-18-045891-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045892/0001209191-18-045892-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009006/0001209191-19-009006-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009024/0001209191-19-009024-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009028/0001209191-19-009028-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/0001209191-19-009031-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009034/0001209191-19-009034-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009036/0001209191-19-009036-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009038/0001209191-19-009038-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009043/0001209191-19-009043-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009044/0001209191-19-009044-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009046/0001209191-19-009046-index.htm
2019-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119046820/0001209191-19-046820-index.htm
2019-09-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050888/0001209191-19-050888-index.htm
2019-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050889/0001209191-19-050889-index.htm
2019-11-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059923/0001209191-19-059923-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059924/0001209191-19-059924-index.htm
2019-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119060981/0001209191-19-060981-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009309/0001209191-20-009309-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009316/0001209191-20-009316-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009322/0001209191-20-009322-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009325/0001209191-20-009325-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009327/0001209191-20-009327-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009329/0001209191-20-009329-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2020-07-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042503/0001209191-20-042503-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042505/0001209191-20-042505-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042506/0001209191-20-042506-index.htm
2020-07-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044257/0001209191-20-044257-index.htm
2020-07-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044259/0001209191-20-044259-index.htm
2019-11-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000121465919007372/0001214659-19-007372-index.htm
2018-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417318000087/0001274173-18-000087-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000033/0001274173-19-000033-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000125/0001274173-19-000125-index.htm
2019-08-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924419000074/0001319244-19-000074-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924420000020/0001319244-20-000020-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000020/0001370053-18-000020-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000022/0001370053-18-000022-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000026/0001370053-18-000026-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000027/0001370053-18-000027-index.htm
2018-05-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000029/0001370053-18-000029-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000031/0001370053-18-000031-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000036/0001370053-18-000036-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000037/0001370053-18-000037-index.htm
2018-09-1410-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000041/0001370053-18-000041-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000042/0001370053-18-000042-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000043/0001370053-18-000043-index.htm
2018-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000046/0001370053-18-000046-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000051/0001370053-18-000051-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000052/0001370053-18-000052-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000004/0001370053-19-000004-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000006/0001370053-19-000006-index.htm
2019-02-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000007/0001370053-19-000007-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000013/0001370053-19-000013-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000014/0001370053-19-000014-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000018/0001370053-19-000018-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000019/0001370053-19-000019-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000021/0001370053-19-000021-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000026/0001370053-19-000026-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000027/0001370053-19-000027-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000029/0001370053-19-000029-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000031/0001370053-19-000031-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000035/0001370053-19-000035-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000041/0001370053-19-000041-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000042/0001370053-19-000042-index.htm
2020-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000003/0001370053-20-000003-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000007/0001370053-20-000007-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000009/0001370053-20-000009-index.htm
2020-03-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000010/0001370053-20-000010-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000013/0001370053-20-000013-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000019/0001370053-20-000019-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000020/0001370053-20-000020-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000025/0001370053-20-000025-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000026/0001370053-20-000026-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000042/0001370053-20-000042-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000045/0001370053-20-000045-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000050/0001370053-20-000050-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000051/0001370053-20-000051-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000053/0001370053-20-000053-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000057/0001370053-20-000057-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000064/0001370053-20-000064-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000065/0001370053-20-000065-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000230/0001623632-20-000230-index.htm
2020-04-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000855/0001623632-20-000855-index.htm

AnaptysBio, Inc (ANAB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AnaptysBio, Inc (ANAB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 77%
Institutional Ownership: 10622%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-03Dominic PiscitelliChief Financial OfficerSell1,100.0075.8183,390.010.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell4,820.0072.24348,212.2210,022.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell6,624.0074.33492,361.921,100.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-09-07Marco LondeiChief Medical OfficerBuy142,857.000.7099,999.90144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell6,741.0068.47461,577.84144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell18,604.0071.331,327,060.5314,842.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell8,002.0067.57540,683.94151,618.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy8,048.000.705,633.60152,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell3,185.0066.38211,416.16159,620.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell12,120.0065.36792,177.74162,805.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy22,000.006.93152,460.00174,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-06-10Hamza SuriaPresident, CEOSell454.0076.3134,644.7417,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell1,994.0075.86151,270.8218,090.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell5,000.0074.68373,412.5020,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell14,894.0070.041,043,195.1222,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,003.0074.50149,219.0922,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,048.0073.43150,383.8224,380.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-10Hamza SuriaPresident, CEOSell6,440.0073.70474,637.0225,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell6,009.0072.45435,358.6626,428.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-04-16Nicholas LydonDirectorSell2,222.0090.26200,549.05271,106.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell2,803.0089.42250,631.37273,328.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-08Hamza SuriaPresident, CEOBuy22,428.002.5958,088.5227,426.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-04-16Nicholas LydonDirectorSell4,250.0088.30375,267.35276,131.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-11-22Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0027,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2018-04-16Nicholas LydonDirectorSell9,425.0087.46824,340.66280,381.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy1,428.002.243,198.7228,854.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-04-16Nicholas LydonDirectorSell1,390.0086.15119,752.95289,806.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell10,310.0085.11877,491.32291,196.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-12-11Hamza SuriaPresident, CEOSell4,998.0070.83354,008.3430,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOSell8,324.0072.88606,618.1630,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-14Hamza SuriaPresident, CEOSell7,800.0070.51549,978.7830,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2019-01-14Hamza SuriaPresident, CEOSell12,240.0071.10870,304.3930,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-04-16Nicholas LydonDirectorSell2,600.0084.18218,879.96301,506.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-06-10Hamza SuriaPresident, CEOSell8,540.0072.64620,384.8831,524.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerBuy10,060.000.707,042.0032,437.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell3,554.0070.34249,974.1433,446.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy6,208.001.619,994.8835,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-12-10Hamza SuriaPresident, CEOSell4,964.0072.48359,805.1235,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-12-10J. Anthony WareDirectorBuy3,600.0014.0550,580.003,600.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerBuy37,000.0011.34419,580.0037,000.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell4,181.0069.29289,686.4437,271.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2020-02-05Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0037,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2018-12-14Hamza SuriaPresident, CEOSell9,084.0069.68632,967.6737,864.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-12Hamza SuriaPresident, CEOSell9,673.0071.92695,717.9538,388.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell10,347.0071.49739,700.8240,026.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-04-17Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0040,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-01-15Marco LondeiChief Medical OfficerBuy19,075.006.93132,189.7541,452.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-14Hamza SuriaPresident, CEOSell27,760.0070.651,961,227.3442,304.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOSell24,844.0068.891,711,428.6346,948.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2020-03-10Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0047,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2018-12-12Hamza SuriaPresident, CEOSell12,003.0071.11853,480.5248,061.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell15,276.0070.571,078,082.3150,373.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOBuy30,000.001.1233,600.0060,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOBuy30,587.001.1234,257.4465,649.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-11-27Marco LondeiChief Medical OfficerBuy46,202.006.93320,179.8668,579.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-01-14Hamza SuriaPresident, CEOBuy40,000.001.1244,800.0070,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOBuy41,728.001.1246,735.3671,792.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell2,298.0073.18168,158.687,724.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm